{
 "generated_at": "2026-10-02T05:42:06-04:00",
 "generated_at_h": "2026-10-02 05:42 ET",
 "mode": "nightly",
 "window_months": 12,
 "trials": [
  {
   "nct": "NCT04768972",
   "title": "FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-06-17",
   "enrollment": 89,
   "conditions": "Amyotrophic Lateral Sclerosis",
   "interventions": "ION363; Placebo",
   "pc_type": "ACTUAL",
   "status_verified": "2026-07",
   "last_update": "2026-07-21",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05543616",
   "title": "A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Childr",
   "sponsor": "BioNTech SE",
   "status": "COMPLETED",
   "primary_completion": "2026-07-10",
   "enrollment": 4338,
   "conditions": "SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19",
   "interventions": "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose; Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose; Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose",
   "pc_type": "ACTUAL",
   "status_verified": "2026-08",
   "last_update": "2026-08-06",
   "lead_class": "INDUSTRY",
   "collaborators": "Pfizer",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": true,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06411288",
   "title": "Global Study of Del-desiran for the Treatment of DM1",
   "sponsor": "Avidity Biosciences, Inc.",
   "status": "COMPLETED",
   "primary_completion": "2026-07-23",
   "enrollment": 159,
   "conditions": "DM1; Myotonic Dystrophy; Myotonic Dystrophy 1",
   "interventions": "AOC 1001 (del-desiran); Placebo",
   "pc_type": "ACTUAL",
   "status_verified": "2026-08",
   "last_update": "2026-09-01",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "RNA",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06067230",
   "title": "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respir",
   "sponsor": "ModernaTX, Inc.",
   "status": "COMPLETED",
   "primary_completion": "2026-07-24",
   "enrollment": 1153,
   "conditions": "Respiratory Syncytial Virus",
   "interventions": "mRNA-1345",
   "pc_type": "ACTUAL",
   "status_verified": "2026-08",
   "last_update": "2026-08-20",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "MRNA",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07222384",
   "title": "A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 ",
   "sponsor": "BioNTech SE",
   "status": "COMPLETED",
   "primary_completion": "2026-07-24",
   "enrollment": 344,
   "conditions": "COVID-19; SARS-COV-2 Infection",
   "interventions": "BNT162b2 (2025/2026 formulation)",
   "pc_type": "ACTUAL",
   "status_verified": "2026-08",
   "last_update": "2026-08-07",
   "lead_class": "INDUSTRY",
   "collaborators": "Pfizer",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": true,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT04724369",
   "title": "Open-Label Study of 18F-mFBG for Imaging Neuroblastoma",
   "sponsor": "Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)",
   "status": "COMPLETED",
   "primary_completion": "2026-07-30",
   "enrollment": 43,
   "conditions": "Neuroblastoma",
   "interventions": "18F-MFBG",
   "pc_type": "ACTUAL",
   "status_verified": "2026-09",
   "last_update": "2026-09-29",
   "lead_class": "INDUSTRY",
   "collaborators": "New Approaches to Neuroblastoma Therapy Consortium; Memorial Sloan Kettering Cancer Center",
   "phases": "PHASE3",
   "ticker": "ILMN",
   "pass": "phase3",
   "routine": true,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07300839",
   "title": "A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age",
   "sponsor": "BioNTech SE",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-07-31",
   "enrollment": 5240,
   "conditions": "COVID-19; SARS-COV-2 Infection",
   "interventions": "BNT162b2 Vaccine; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-04",
   "last_update": "2026-04-13",
   "lead_class": "INDUSTRY",
   "collaborators": "Pfizer",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": true,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06018337",
   "title": "A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Recep",
   "sponsor": "DualityBio Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-08-12",
   "enrollment": 541,
   "conditions": "Metastatic Breast Cancer",
   "interventions": "DB-1303/BNT323; Capecitabine; Paclitaxel",
   "pc_type": "ACTUAL",
   "status_verified": "2026-09",
   "last_update": "2026-09-24",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05693142",
   "title": "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (",
   "sponsor": "REGENXBIO Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-09",
   "enrollment": 65,
   "conditions": "Duchenne Muscular Dystrophy",
   "interventions": "RGX-202",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-21",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2|PHASE3",
   "ticker": "RGNX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05407636",
   "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD",
   "sponsor": "AbbVie",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-10",
   "enrollment": 735,
   "conditions": "AMD; nAMD; Wet Age-related Macular Degeneration",
   "interventions": "ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; Aflibercept (EYLEA\u00ae)",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-08-03",
   "lead_class": "INDUSTRY",
   "collaborators": "REGENXBIO Inc.",
   "phases": "PHASE3",
   "ticker": "RGNX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05164094",
   "title": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old",
   "sponsor": "ModernaTX, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-10-05",
   "enrollment": 867,
   "conditions": "Epstein-Barr Virus Infection",
   "interventions": "mRNA-1189; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-05",
   "last_update": "2026-05-06",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "MRNA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT03368742",
   "title": "Microdystrophin Gene Transfer Study in Adolescents and Children With DMD",
   "sponsor": "Solid Biosciences Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-10-15",
   "enrollment": 12,
   "conditions": "Duchenne Muscular Dystrophy",
   "interventions": "SGT-001",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-10",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "SLDB",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05918133",
   "title": "A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC",
   "sponsor": "Biotheus Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-10-30",
   "enrollment": 42,
   "conditions": "TNBC",
   "interventions": "PM8002; nab-paclitaxel",
   "pc_type": "ESTIMATED",
   "status_verified": "2024-11",
   "last_update": "2025-03-11",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT03992430",
   "title": "A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Du",
   "sponsor": "Sarepta Therapeutics, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-10-31",
   "enrollment": 160,
   "conditions": "Muscular Dystrophy, Duchenne",
   "interventions": "Eteplirsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-02",
   "last_update": "2026-02-27",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "SRPT",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT04486378",
   "title": "A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in P",
   "sponsor": "BioNTech SE",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-11",
   "enrollment": 327,
   "conditions": "Colorectal Cancer Stage II; Colorectal Cancer Stage III",
   "interventions": "RO7198457 intravenous (IV); Observational group (no intervention)",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-28",
   "lead_class": "INDUSTRY",
   "collaborators": "Genentech, Inc.",
   "phases": "PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05095727",
   "title": "A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Typ",
   "sponsor": "ModernaTX, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-11-30",
   "enrollment": 15,
   "conditions": "Glycogen Storage Disease",
   "interventions": "mRNA-3745",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-12",
   "last_update": "2025-12-15",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "MRNA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06063850",
   "title": "AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epile",
   "sponsor": "UniQure Biopharma B.V.",
   "status": "RECRUITING",
   "primary_completion": "2026-11-30",
   "enrollment": 12,
   "conditions": "Mesial Temporal Lobe Epilepsy",
   "interventions": "AAV9-hSyn1-miGRIK2",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-24",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "QURE",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05392114",
   "title": "A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Tr",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-12",
   "enrollment": 154,
   "conditions": "Hereditary Angioedema",
   "interventions": "Donidalorsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-12",
   "last_update": "2025-12-12",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT04704921",
   "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subr",
   "sponsor": "AbbVie",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-12",
   "enrollment": 671,
   "conditions": "AMD; nAMD; Wet Age-related Macular Degeneration",
   "interventions": "ABBV-RGX-314; ABBV-RGX-314; Ranibizumab (LUCENTIS\u00ae)",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-04",
   "last_update": "2026-04-28",
   "lead_class": "INDUSTRY",
   "collaborators": "REGENXBIO Inc.",
   "phases": "PHASE2|PHASE3",
   "ticker": "RGNX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05482516",
   "title": "Evaluating Novel Therapies in ctDNA Positive GI Cancers",
   "sponsor": "Georgetown University",
   "status": "RECRUITING",
   "primary_completion": "2026-12",
   "enrollment": 20,
   "conditions": "Colon Adenocarcinoma; Rectal Adenocarcinoma; Gastric Adenocarcinoma",
   "interventions": "Atezolizumab; Bevacizumab",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-01",
   "last_update": "2026-09-14",
   "lead_class": "OTHER",
   "collaborators": "Genentech, Inc.; Natera, Inc.",
   "phases": "PHASE3",
   "ticker": "NTRA",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05885464",
   "title": "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute",
   "sponsor": "Beam Therapeutics Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-12",
   "enrollment": 5,
   "conditions": "Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia",
   "interventions": "BEAM-201",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-01",
   "last_update": "2025-01-13",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "BEAM",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06109181",
   "title": "Gene Therapy for ACM Due to a PKP2 Pathogenic Variant",
   "sponsor": "Lexeo Therapeutics",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-12",
   "enrollment": 10,
   "conditions": "Arrhythmogenic Cardiomyopathy; PKP2-ACM; PKP2-ARVC",
   "interventions": "LX2020",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-11",
   "last_update": "2025-11-12",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "LXEO",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06038474",
   "title": "Descartes-08 for Patients With Systemic Lupus Erythematosus",
   "sponsor": "Cartesian Therapeutics",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-12-01",
   "enrollment": 6,
   "conditions": "Systemic Lupus Erythematosus (SLE)",
   "interventions": "Descartes-08",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-03",
   "last_update": "2026-03-27",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "RNAC",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06799247",
   "title": "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach t",
   "sponsor": "Cartesian Therapeutics",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2026-12-30",
   "enrollment": 128,
   "conditions": "Myasthaenia Gravis",
   "interventions": "Decartes-08; Placebo Drug",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-09-01",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "RNAC",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06138743",
   "title": "Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy",
   "sponsor": "Sarepta Therapeutics, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2026-12-31",
   "enrollment": 78,
   "conditions": "Myotonic Dystrophy 1",
   "interventions": "SRP-1003 IV Infusion; Placebo IV Infusion; SRP-1003 SC Injection",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-11",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "SRPT",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05879055",
   "title": "A Study of PM8002 in Combination With Chemotherapy in Patients With NEN",
   "sponsor": "Biotheus Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-01-01",
   "enrollment": 31,
   "conditions": "Neuroendocrine Neoplasm",
   "interventions": "PM8002; FOLFIRI",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-09",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05686226",
   "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",
   "sponsor": "Christian Hinrichs",
   "status": "RECRUITING",
   "primary_completion": "2027-01-01",
   "enrollment": 20,
   "conditions": "Cervical Cancer; Throat Cancer; Oropharynx Cancer",
   "interventions": "E7 TCR-T cells; Aldesleukin",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-06",
   "last_update": "2026-06-12",
   "lead_class": "OTHER",
   "collaborators": "National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.",
   "phases": "PHASE2",
   "ticker": "IOVA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06616532",
   "title": "PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment ",
   "sponsor": "Biotheus Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-01-25",
   "enrollment": 404,
   "conditions": "SCLC",
   "interventions": "PM8002; Paclitaxel; Topotecan",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-04",
   "last_update": "2026-05-22",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07496450",
   "title": "A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults",
   "sponsor": "ModernaTX, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-01-28",
   "enrollment": 4050,
   "conditions": "Influenza",
   "interventions": "mRNA-1018-H5; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-11",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "MRNA",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06592794",
   "title": "A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants \u226518 Years of A",
   "sponsor": "ModernaTX, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-02-15",
   "enrollment": 37864,
   "conditions": "Acute Gastroenteritis; Norovirus Acute Gastroenteritis",
   "interventions": "mRNA-1403; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-05",
   "last_update": "2026-05-13",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "MRNA",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05681351",
   "title": "CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants W",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-03",
   "enrollment": 885,
   "conditions": "Severe Hypertriglyceridemia",
   "interventions": "Olezarsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-11",
   "last_update": "2025-12-01",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06872125",
   "title": "A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in ",
   "sponsor": "Stoke Therapeutics, Inc",
   "status": "RECRUITING",
   "primary_completion": "2027-03",
   "enrollment": 170,
   "conditions": "Dravet Syndrome",
   "interventions": "zorevunersen; Sham Comparator",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-24",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "STOK",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05683457",
   "title": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus ",
   "sponsor": "ModernaTX, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-03-06",
   "enrollment": 84,
   "conditions": "Cytomegalovirus Infection",
   "interventions": "mRNA-1647; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-10",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "MRNA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT04798235",
   "title": "First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Ganglio",
   "sponsor": "Dr. Anupam Sehgal",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-03-12",
   "enrollment": 3,
   "conditions": "Infantile GM2 Gangliosidosis (Disorder)",
   "interventions": "TSHA-101",
   "pc_type": "ESTIMATED",
   "status_verified": "2023-05",
   "last_update": "2023-05-09",
   "lead_class": "OTHER",
   "collaborators": "Taysha Gene Therapies, Inc.; GlycoNet",
   "phases": "PHASE1|PHASE2",
   "ticker": "TSHA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06153966",
   "title": "PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynami",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-04",
   "enrollment": 85,
   "conditions": "Prion Disease",
   "interventions": "ION717; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-18",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "IONS",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07798648",
   "title": "A Study of COVID-19 Vaccine(s) in Children and Adults",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2027-04-21",
   "enrollment": 700,
   "conditions": "COVID-19 Vaccines",
   "interventions": "BNT162b2; BNT162b2; BNT162b2",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-28",
   "lead_class": "INDUSTRY",
   "collaborators": "Pfizer",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": true,
   "first_seen": "2026-09-02"
  },
  {
   "nct": "NCT06305767",
   "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With ",
   "sponsor": "Merck Sharp & Dohme LLC",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-04-23",
   "enrollment": 230,
   "conditions": "Bladder Cancer",
   "interventions": "Pembrolizumab; Intismeran autogene; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-01",
   "last_update": "2026-01-13",
   "lead_class": "INDUSTRY",
   "collaborators": "ModernaTX, Inc.",
   "phases": "PHASE1|PHASE2",
   "ticker": "MRNA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07463846",
   "title": "A Study to Evaluate ALN-2232 in Participants With Obesity",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "RECRUITING",
   "primary_completion": "2027-04-27",
   "enrollment": 156,
   "conditions": "Obesity",
   "interventions": "ALN-2232; Placebo; Tirzepatide",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-16",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "ALNY",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06244082",
   "title": "Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutation",
   "sponsor": "Avidity Biosciences, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-04-30",
   "enrollment": 39,
   "conditions": "DMD; Duchenne Muscular Dystrophy; Duchenne",
   "interventions": "AOC 1044",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-30",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "RNA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT03449108",
   "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Tripl",
   "sponsor": "M.D. Anderson Cancer Center",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-04-30",
   "enrollment": 30,
   "conditions": "Bone Sarcoma; Dedifferentiated Chondrosarcoma; Giant Cell Tumor of Bone",
   "interventions": "Aldesleukin; Autologous Tumor Infiltrating Lymphocytes LN-145; Autologous Tumor Infiltrating Lymphocytes LN-145-S1",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-05",
   "last_update": "2026-05-22",
   "lead_class": "OTHER",
   "collaborators": "Iovance Biotherapeutics, Inc.; National Cancer Institute (NCI)",
   "phases": "PHASE2",
   "ticker": "IOVA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07133750",
   "title": "PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Ca",
   "sponsor": "Biotheus Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-05",
   "enrollment": 100,
   "conditions": "CRC (Colorectal Cancer)",
   "interventions": "PM8002; Chemotherapy Regimen 1; Chemotherapy Regimen 2",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-23",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06138639",
   "title": "A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)",
   "sponsor": "Solid Biosciences Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-05-06",
   "enrollment": 60,
   "conditions": "Duchenne Muscular Dystrophy",
   "interventions": "SGT-003",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-08",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "SLDB",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07465224",
   "title": "A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitu",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "RECRUITING",
   "primary_completion": "2027-05-28",
   "enrollment": 24,
   "conditions": "Type 2 Diabetes Mellitus (T2DM)",
   "interventions": "ALN-4324; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-16",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "ALNY",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05881408",
   "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxep",
   "sponsor": "Sarepta Therapeutics, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-05-31",
   "enrollment": 148,
   "conditions": "Duchenne Muscular Dystrophy",
   "interventions": "delandistrogene moxeparvovec; placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-05",
   "last_update": "2026-05-22",
   "lead_class": "INDUSTRY",
   "collaborators": "Hoffmann-La Roche",
   "phases": "PHASE3",
   "ticker": "SRPT",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05185843",
   "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Fam",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-06",
   "enrollment": 24,
   "conditions": "Familial Chylomicronemia Syndrome",
   "interventions": "Olezarsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-12",
   "last_update": "2025-12-12",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07379580",
   "title": "A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity A",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2027-06",
   "enrollment": 310,
   "conditions": "Mpox (Monkeypox); Smallpox; Orthopoxvirus Infection",
   "interventions": "BNT166a; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-11",
   "lead_class": "INDUSTRY",
   "collaborators": "Coalition for Epidemic Preparedness Innovations",
   "phases": "PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06449209",
   "title": "Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With ",
   "sponsor": "BioNTech SE",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-06",
   "enrollment": 110,
   "conditions": "Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer",
   "interventions": "BNT327 Dose Level 1 (DL1); BNT327 Dose Level 2 (DL2); Etoposide",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-14",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06747858",
   "title": "Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis",
   "sponsor": "Arcturus Therapeutics, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-06",
   "enrollment": 33,
   "conditions": "Cystic Fibrosis; CFTR Gene Mutation",
   "interventions": "ARCT-032",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-05",
   "last_update": "2026-05-08",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "ARCT",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05329649",
   "title": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle C",
   "sponsor": "Vertex Pharmaceuticals Incorporated",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-06-06",
   "enrollment": 13,
   "conditions": "Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance",
   "interventions": "CTX001",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-06",
   "last_update": "2026-07-01",
   "lead_class": "INDUSTRY",
   "collaborators": "CRISPR Therapeutics",
   "phases": "PHASE3",
   "ticker": "CRSP",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07575308",
   "title": "HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients Wit",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "RECRUITING",
   "primary_completion": "2027-06-30",
   "enrollment": 24,
   "conditions": "Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB)",
   "interventions": "ALN-6400",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-18",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "ALNY",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06672237",
   "title": "A Phase 3 Study of NTLA-2001 in ATTRv-PN",
   "sponsor": "Intellia Therapeutics",
   "status": "RECRUITING",
   "primary_completion": "2027-07",
   "enrollment": 60,
   "conditions": "Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease",
   "interventions": "nexiguran ziclumeran; Normal Saline as Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-04",
   "last_update": "2026-04-16",
   "lead_class": "INDUSTRY",
   "collaborators": "Regeneron Pharmaceuticals",
   "phases": "PHASE3",
   "ticker": "NTLA",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06419621",
   "title": "PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanc",
   "sponsor": "Biotheus Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-07",
   "enrollment": 392,
   "conditions": "Triple Negative Breast Cancer(TNBC)",
   "interventions": "PM8002; Nab-Paclitaxel; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-29",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06914609",
   "title": "REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-08",
   "enrollment": 156,
   "conditions": "Angelman Syndrome",
   "interventions": "obudanersen; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-29",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05150691",
   "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors",
   "sponsor": "DualityBio Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-08",
   "enrollment": 796,
   "conditions": "HER2-positive Advanced Solid Tumor",
   "interventions": "DB-1303/BNT323; Pertuzumab Injection; Ritonavir",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-27",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE1|PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-28"
  },
  {
   "nct": "NCT06393712",
   "title": "A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-08-09",
   "enrollment": 210,
   "conditions": "Cerebral Amyloid Angiopathy",
   "interventions": "Placebo; ALN-APP",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-18",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "ALNY",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05438329",
   "title": "First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors",
   "sponsor": "DualityBio Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-08-13",
   "enrollment": 1123,
   "conditions": "Advanced Solid Tumor",
   "interventions": "DB-1305/BNT325; Pembrolizumab; BNT327",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-05",
   "last_update": "2026-05-12",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE1|PHASE2",
   "ticker": "BNTX",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05671510",
   "title": "ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors",
   "sponsor": "OncoC4, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-08-31",
   "enrollment": 630,
   "conditions": "Non Small Cell Lung Cancer",
   "interventions": "Gotistobart; Docetaxel",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-13",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT04159103",
   "title": "Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia",
   "sponsor": "ModernaTX, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-08-31",
   "enrollment": 77,
   "conditions": "Propionic Acidemia",
   "interventions": "mRNA-3927",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-01",
   "last_update": "2026-01-22",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "MRNA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-31"
  },
  {
   "nct": "NCT06845202",
   "title": "A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight t",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-08-31",
   "enrollment": 105,
   "conditions": "Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)",
   "interventions": "ALN-4324; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-16",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "ALNY",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-08-31"
  },
  {
   "nct": "NCT07604974",
   "title": "A Study to Assess the Safety, Tolerability and Efficacy of ION775",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-09",
   "enrollment": 72,
   "conditions": "Hypertriglyceridemia; Severe Hypertriglyceridemia",
   "interventions": "ION775",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-03",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2",
   "ticker": "IONS",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-09-01"
  },
  {
   "nct": "NCT06430385",
   "title": "ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynami",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-09",
   "enrollment": 48,
   "conditions": "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome",
   "interventions": "ION440; Sham procedure",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-03",
   "last_update": "2026-03-24",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "IONS",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-09-01"
  },
  {
   "nct": "NCT05361174",
   "title": "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Partici",
   "sponsor": "Iovance Biotherapeutics, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2027-09",
   "enrollment": 53,
   "conditions": "Unresectable Melanoma; Metastatic Melanoma; Stage III Non-small Cell Lung Cancer",
   "interventions": "IOV-4001",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-06",
   "last_update": "2026-06-11",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE1|PHASE2",
   "ticker": "IOVA",
   "pass": "phase2",
   "routine": false,
   "first_seen": "2026-09-01"
  },
  {
   "nct": "NCT05356195",
   "title": "Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dep",
   "sponsor": "Vertex Pharmaceuticals Incorporated",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2027-11-14",
   "enrollment": 16,
   "conditions": "Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn",
   "interventions": "CTX001",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-06",
   "last_update": "2026-07-01",
   "lead_class": "INDUSTRY",
   "collaborators": "CRISPR Therapeutics",
   "phases": "PHASE3",
   "ticker": "CRSP",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06128629",
   "title": "MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis Wit",
   "sponsor": "Intellia Therapeutics",
   "status": "RECRUITING",
   "primary_completion": "2027-12",
   "enrollment": 1200,
   "conditions": "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",
   "interventions": "NTLA-2001; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-03",
   "last_update": "2026-03-27",
   "lead_class": "INDUSTRY",
   "collaborators": "Regeneron Pharmaceuticals",
   "phases": "PHASE3",
   "ticker": "NTLA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06472245",
   "title": "Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer an",
   "sponsor": "OSE Immunotherapeutics",
   "status": "RECRUITING",
   "primary_completion": "2027-12-15",
   "enrollment": 363,
   "conditions": "Patients With Non-Small Cell Lung Cancer",
   "interventions": "OSE2101; Docetaxel; NGS HLAA2 assay",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-23",
   "lead_class": "INDUSTRY",
   "collaborators": "Exystat; GeneDx",
   "phases": "PHASE3",
   "ticker": "WGS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07223203",
   "title": "TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Here",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "RECRUITING",
   "primary_completion": "2027-12-27",
   "enrollment": 125,
   "conditions": "Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN",
   "interventions": "Nucresiran; Vutrisiran",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-15",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "ALNY",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05130450",
   "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial C",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2028-02",
   "enrollment": 60,
   "conditions": "Familial Chylomicronemia Syndrome",
   "interventions": "Olezarsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-12",
   "last_update": "2025-12-12",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06340568",
   "title": "A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy ",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2028-03",
   "enrollment": 480,
   "conditions": "Endometrial Cancer",
   "interventions": "BNT323/DB-1303; Doxorubicin; Paclitaxel",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-17",
   "lead_class": "INDUSTRY",
   "collaborators": "DualityBio Inc.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05727904",
   "title": "Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alo",
   "sponsor": "Iovance Biotherapeutics, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2028-03-01",
   "enrollment": 670,
   "conditions": "Metastatic Melanoma; Unresectable Melanoma; Melanoma",
   "interventions": "Lifileucel plus Pembrolizumab; Pembrolizumab with Optional Crossover Period",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-24",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IOVA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06679946",
   "title": "A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopa",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "ENROLLING_BY_INVITATION",
   "primary_completion": "2028-03-31",
   "enrollment": 700,
   "conditions": "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",
   "interventions": "Vutrisiran",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-02",
   "last_update": "2026-02-20",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "ALNY",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07236606",
   "title": "RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)",
   "sponsor": "REGENXBIO Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2028-04-30",
   "enrollment": 2,
   "conditions": "MPS II; Hunter Syndrome (MPS II)",
   "interventions": "RGX-121-3102",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-06",
   "last_update": "2026-06-04",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "RGNX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07782827",
   "title": "CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children ",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2028-05",
   "enrollment": 30,
   "conditions": "Angelman Syndrome",
   "interventions": "obudanersen",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-28",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-25"
  },
  {
   "nct": "NCT07038200",
   "title": "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD",
   "sponsor": "Avidity Biosciences, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2028-05",
   "enrollment": 200,
   "conditions": "Facioscapulohumeral Muscular Dystrophy; FSHD; FSHD - Facioscapulohumeral Muscular Dystrophy",
   "interventions": "AOC-1020; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-27",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "RNA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT04534205",
   "title": "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113",
   "sponsor": "BioNTech SE",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2028-08",
   "enrollment": 358,
   "conditions": "Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer",
   "interventions": "BNT113; Pembrolizumab",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-21",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE2|PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07004413",
   "title": "Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild",
   "sponsor": "Charite University, Berlin, Germany",
   "status": "NOT_YET_RECRUITING",
   "primary_completion": "2028-10-01",
   "enrollment": 267,
   "conditions": "Colorectal Cancer Metastatic",
   "interventions": "FOLFIRI+cetuximab; Guardant360 ctDNA assay",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-29",
   "lead_class": "OTHER",
   "collaborators": "Guardant Health, Inc.; Merck KGaA, Darmstadt, Germany",
   "phases": "PHASE3",
   "ticker": "GH",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06712355",
   "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2028-12",
   "enrollment": 621,
   "conditions": "Extensive-stage Small-cell Lung Cancer",
   "interventions": "Pumitamig; Atezolizumab; Etoposide",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-09-01",
   "lead_class": "INDUSTRY",
   "collaborators": "Bristol-Myers Squibb",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06712316",
   "title": "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Othe",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2029-01",
   "enrollment": 1580,
   "conditions": "Non-small Cell Lung Cancer",
   "interventions": "Pumitamig; Pembrolizumab; Carboplatin",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-22",
   "lead_class": "INDUSTRY",
   "collaborators": "Bristol-Myers Squibb",
   "phases": "PHASE2|PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07160634",
   "title": "A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT",
   "sponsor": "Solid Biosciences Inc.",
   "status": "RECRUITING",
   "primary_completion": "2029-01",
   "enrollment": 80,
   "conditions": "Duchenne Muscular Dystrophy",
   "interventions": "SGT-003; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-28",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "SLDB",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05174169",
   "title": "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease",
   "sponsor": "NRG Oncology",
   "status": "RECRUITING",
   "primary_completion": "2029-03-10",
   "enrollment": 1912,
   "conditions": "Stage III Colon Cancer",
   "interventions": "Signatera test; mFOLFOX6 3-6 month; CAPOX 3 month",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-02",
   "lead_class": "OTHER",
   "collaborators": "Natera, Inc.; National Cancer Institute (NCI)",
   "phases": "PHASE2|PHASE3",
   "ticker": "NTRA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07587242",
   "title": "A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpa",
   "sponsor": "Avidity Biosciences, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2029-05",
   "enrollment": 70,
   "conditions": "Muscular Dystrophies; Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy); Muscular Disorders, Atrophic",
   "interventions": "AOC 1044; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-09-29",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "RNA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07298447",
   "title": "Donidalorsen Treatment in Children With Hereditary Angioedema",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2029-06",
   "enrollment": 20,
   "conditions": "Hereditary Angioedema (HAE)",
   "interventions": "Donidalorsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-02",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05667493",
   "title": "An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ENROLLING_BY_INVITATION",
   "primary_completion": "2029-08",
   "enrollment": 1400,
   "conditions": "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
   "interventions": "Eplontersen",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-04",
   "last_update": "2026-04-17",
   "lead_class": "INDUSTRY",
   "collaborators": "AstraZeneca",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05071300",
   "title": "A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2029-08",
   "enrollment": 151,
   "conditions": "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",
   "interventions": "Eplontersen",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-12",
   "last_update": "2025-12-04",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05933577",
   "title": "A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk",
   "sponsor": "Merck Sharp & Dohme LLC",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2029-10-26",
   "enrollment": 1089,
   "conditions": "Melanoma",
   "interventions": "Intismeran autogene; Pembrolizumab; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2025-09",
   "last_update": "2025-09-24",
   "lead_class": "INDUSTRY",
   "collaborators": "ModernaTX, Inc.",
   "phases": "PHASE3",
   "ticker": "MRNA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07173751",
   "title": "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Br",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2029-12",
   "enrollment": 558,
   "conditions": "Breast Neoplasms",
   "interventions": "Pumitamig; Nab-paclitaxel/Paclitaxel; Gemcitabine",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-17",
   "lead_class": "INDUSTRY",
   "collaborators": "Bristol-Myers Squibb",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07221357",
   "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy ",
   "sponsor": "Bristol-Myers Squibb",
   "status": "RECRUITING",
   "primary_completion": "2030-02-02",
   "enrollment": 990,
   "conditions": "Untreated, Unresectable, or Metastatic Colorectal Cancer",
   "interventions": "Pumitamig; FOLFOX; FOLFIRI",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-23",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE2|PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07052903",
   "title": "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With ",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "RECRUITING",
   "primary_completion": "2030-05-28",
   "enrollment": 1750,
   "conditions": "Transthyretin Amyloidosis With Cardiomyopathy",
   "interventions": "Nucresiran; Sterile Normal Saline (0.9% NaCl)",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-16",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "ALNY",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT06077760",
   "title": "A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pem",
   "sponsor": "Merck Sharp & Dohme LLC",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2030-06-25",
   "enrollment": 868,
   "conditions": "Non-small Cell Lung Cancer",
   "interventions": "Intismeran autogene; Pembrolizumab; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-18",
   "lead_class": "INDUSTRY",
   "collaborators": "ModernaTX, Inc.",
   "phases": "PHASE3",
   "ticker": "MRNA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07727538",
   "title": "A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pedia",
   "sponsor": "Ionis Pharmaceuticals, Inc.",
   "status": "RECRUITING",
   "primary_completion": "2030-08",
   "enrollment": 12,
   "conditions": "Familial Chylomicronemia Syndrome",
   "interventions": "Olezarsen",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-26",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "IONS",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07361497",
   "title": "A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therap",
   "sponsor": "Bristol-Myers Squibb",
   "status": "RECRUITING",
   "primary_completion": "2030-09-18",
   "enrollment": 850,
   "conditions": "Non-small Cell Lung Cancer (NSCLC)",
   "interventions": "Pumitamig; Durvalumab",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-30",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07181109",
   "title": "Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Establ",
   "sponsor": "Alnylam Pharmaceuticals",
   "status": "RECRUITING",
   "primary_completion": "2030-09-23",
   "enrollment": 11000,
   "conditions": "High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk",
   "interventions": "Zilebesiran; Placebo",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-18",
   "lead_class": "INDUSTRY",
   "collaborators": "Hoffmann-La Roche",
   "phases": "PHASE3",
   "ticker": "ALNY",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07008469",
   "title": "Global Open-Label Extension Study of Del-desiran for the Treatment of DM1",
   "sponsor": "Avidity Biosciences, Inc.",
   "status": "ENROLLING_BY_INVITATION",
   "primary_completion": "2030-10",
   "enrollment": 199,
   "conditions": "Myotonic Dystrophy Type 1; DM1; Myotonic Dystrophy",
   "interventions": "Del-desiran (AOC 1001)",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-19",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "RNA",
   "pass": "phase3-far",
   "routine": true,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07221149",
   "title": "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy ",
   "sponsor": "Bristol-Myers Squibb",
   "status": "RECRUITING",
   "primary_completion": "2030-11-08",
   "enrollment": 690,
   "conditions": "Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",
   "interventions": "Pumitamig; Folfox; Capox",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-30",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech SE",
   "phases": "PHASE2|PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07365995",
   "title": "A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate C",
   "sponsor": "BioNTech SE",
   "status": "RECRUITING",
   "primary_completion": "2031-02",
   "enrollment": 736,
   "conditions": "Metastatic Castration-resistant Prostate Cancer",
   "interventions": "BNT324; Docetaxel; Prednisone/prednisolone",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-09",
   "last_update": "2026-09-18",
   "lead_class": "INDUSTRY",
   "collaborators": "BioNTech (Shanghai) Pharmaceuticals Co., Ltd.; DualityBio Inc.",
   "phases": "PHASE3",
   "ticker": "BNTX",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT07480564",
   "title": "Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <",
   "sponsor": "Taysha Gene Therapies, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2031-06",
   "enrollment": 4,
   "conditions": "Rett Syndrome",
   "interventions": "TSHA-102",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-08",
   "last_update": "2026-08-19",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "TSHA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  },
  {
   "nct": "NCT05606614",
   "title": "A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal",
   "sponsor": "Taysha Gene Therapies, Inc.",
   "status": "ACTIVE_NOT_RECRUITING",
   "primary_completion": "2031-06",
   "enrollment": 17,
   "conditions": "Rett Syndrome",
   "interventions": "TSHA-102",
   "pc_type": "ESTIMATED",
   "status_verified": "2026-07",
   "last_update": "2026-07-07",
   "lead_class": "INDUSTRY",
   "collaborators": "",
   "phases": "PHASE3",
   "ticker": "TSHA",
   "pass": "phase3-far",
   "routine": false,
   "first_seen": "2026-08-19"
  }
 ],
 "diffs": {
  "new": [],
  "removed": [
   {
    "date": "2026-10-01",
    "nct": "NCT05639972",
    "pass": "phase2",
    "pc_type": "ESTIMATED",
    "status": "RECRUITING",
    "ticker": "IOVA",
    "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associa"
   },
   {
    "date": "2026-10",
    "nct": "NCT06584071",
    "pass": "phase2",
    "pc_type": "ESTIMATED",
    "status": "NOT_YET_RECRUITING",
    "ticker": "BNTX",
    "title": "A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC"
   }
  ],
  "slipped": [],
  "pulled_in": [],
  "firmed": [],
  "status_changed": [],
  "prev_date": "2026-10-01"
 },
 "discovery": {
  "as_of": "2026-09-27",
  "candidates": [
   {
    "ticker": "IVBXF",
    "company": "Innovent Biologics Inc/ADR",
    "trials": [
     {
      "nct": "NCT05116462",
      "date": "2026-09-30",
      "title": "Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer",
      "conditions": "Non-Small Cell Lung Cancer",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2026-09-30",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "SKBBY",
    "company": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./ADR",
    "trials": [
     {
      "nct": "NCT06448312",
      "date": "2026-11",
      "title": "A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With ",
      "conditions": "Non-Small Cell Lung Cancer",
      "keyword": "cell therapy"
     },
     {
      "nct": "NCT06711900",
      "date": "2026-12",
      "title": "A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination Wit",
      "conditions": "Non-Small Cell Lung Cancer",
      "keyword": "cell therapy"
     },
     {
      "nct": "NCT06670196",
      "date": "2027-05",
      "title": "A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epid",
      "conditions": "Non-Small Cell Lung Cancer",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2026-11",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "KPTI",
    "company": "Karyopharm Therapeutics Inc.",
    "trials": [
     {
      "nct": "NCT04442022",
      "date": "2026-12",
      "title": "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor ",
      "conditions": "Relapsed/Refractory Diffuse Large B-cell Lymphoma",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2026-12",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "HROW",
    "company": "HARROW, INC.",
    "trials": [
     {
      "nct": "NCT07832552",
      "date": "2026-12",
      "title": "A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE\u00ae (Injectable Suspension) f",
      "conditions": "Postoperative Ocular Inflammation; Postoperative Ocular Pain",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2026-12",
    "first_seen": "2026-09-27"
   },
   {
    "ticker": "SVA",
    "company": "SINOVAC BIOTECH LTD",
    "trials": [
     {
      "nct": "NCT07055295",
      "date": "2026-12-30",
      "title": "Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Proph",
      "conditions": "Rabies",
      "keyword": "cell therapy"
     },
     {
      "nct": "NCT07793227",
      "date": "2027-09-15",
      "title": "Phase \u2162 Clinical Trial of an Inactivated Hepatitis A Vaccine",
      "conditions": "Hepatitis A Vaccine",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2026-12-30",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "ONC",
    "company": "BeOne Medicines Ltd.",
    "trials": [
     {
      "nct": "NCT04170283",
      "date": "2026-12-31",
      "title": "A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell ",
      "conditions": "B-cell Malignancies",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2026-12-31",
    "first_seen": "2026-08-30"
   },
   {
    "ticker": "OCGN",
    "company": "Ocugen, Inc.",
    "trials": [
     {
      "nct": "NCT06388200",
      "date": "2027-02-12",
      "title": "A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa",
      "conditions": "Retinitis Pigmentosa",
      "keyword": "gene therapy"
     }
    ],
    "nearest": "2027-02-12",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "HURA",
    "company": "TuHURA Biosciences, Inc./NV",
    "trials": [
     {
      "nct": "NCT06947928",
      "date": "2027-03-31",
      "title": "Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Na",
      "conditions": "Advanced Or Metastatic Merkel Cell Carcinoma",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2027-03-31",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "FDMT",
    "company": "4D Molecular Therapeutics, Inc.",
    "trials": [
     {
      "nct": "NCT06864988",
      "date": "2027-06",
      "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degene",
      "conditions": "Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "keyword": "gene therapy"
     }
    ],
    "nearest": "2027-06",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "DNLI",
    "company": "Denali Therapeutics Inc.",
    "trials": [
     {
      "nct": "NCT06075537",
      "date": "2027-06",
      "title": "An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alf",
      "conditions": "Mucopolysaccharidosis II",
      "keyword": "gene therapy"
     }
    ],
    "nearest": "2027-06",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "MESO",
    "company": "MESOBLAST LTD",
    "trials": [
     {
      "nct": "NCT06325566",
      "date": "2027-07",
      "title": "Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to",
      "conditions": "Degenerative Disc Disease",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2027-07",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "MAIA",
    "company": "MAIA Biotechnology, Inc.",
    "trials": [
     {
      "nct": "NCT06908304",
      "date": "2027-07-31",
      "title": "A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced",
      "conditions": "Carcinoma, Non-Small -Cell Lung",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2027-07-31",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "RARE",
    "company": "Ultragenyx Pharmaceutical Inc.",
    "trials": [
     {
      "nct": "NCT04360265",
      "date": "2027-08",
      "title": "Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS",
      "conditions": "Mucopolysaccharidosis IIIA; MPS IIIA; Sanfilippo Syndrome",
      "keyword": "gene therapy"
     },
     {
      "nct": "NCT05345171",
      "date": "2027-09",
      "title": "Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) D",
      "conditions": "OTC Deficiency",
      "keyword": "gene therapy"
     }
    ],
    "nearest": "2027-08",
    "first_seen": "2026-08-19"
   },
   {
    "ticker": "TLX",
    "company": "Telix Pharmaceuticals Ltd",
    "trials": [
     {
      "nct": "NCT07197580",
      "date": "2027-08-31",
      "title": "Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurr",
      "conditions": "ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC)",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2027-08-31",
    "first_seen": "2026-09-06"
   },
   {
    "ticker": "KYTX",
    "company": "Kyverna Therapeutics, Inc.",
    "trials": [
     {
      "nct": "NCT06193889",
      "date": "2027-09",
      "title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Ge",
      "conditions": "Myasthenia Gravis; Generalized Myasthenia Gravis",
      "keyword": "cell therapy"
     }
    ],
    "nearest": "2027-09",
    "first_seen": "2026-09-06"
   }
  ],
  "sponsor_freq": [
   {
    "sponsor": "Merck Sharp & Dohme LLC",
    "n": 7,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "AstraZeneca",
    "n": 6,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Novartis Pharmaceuticals",
    "n": 5,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Qilu Pharmaceutical Co., Ltd.",
    "n": 4,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Changchun GeneScience Pharmaceutical Co., Ltd.",
    "n": 4,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Akeso",
    "n": 3,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",
    "n": 3,
    "category": "candidate",
    "ticker": "SKBBY"
   },
   {
    "sponsor": "Amgen",
    "n": 3,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Daiichi Sankyo",
    "n": 2,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Shanghai JMT-Bio Inc.",
    "n": 2,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "AbbVie",
    "n": 2,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "REGENXBIO Inc.",
    "n": 2,
    "category": "watchlist",
    "ticker": ""
   },
   {
    "sponsor": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",
    "n": 2,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Takeda",
    "n": 2,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Sichuan Baili Pharmaceutical Co., Ltd.",
    "n": 2,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",
    "n": 2,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Suzhou Suncadia Biopharmaceuticals Co., Ltd.",
    "n": 2,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Sinovac Biotech Co., Ltd",
    "n": 2,
    "category": "candidate",
    "ticker": "SVA"
   },
   {
    "sponsor": "Hoffmann-La Roche",
    "n": 2,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "n": 2,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Regeneron Pharmaceuticals",
    "n": 2,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "n": 2,
    "category": "candidate",
    "ticker": "RARE"
   },
   {
    "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
    "n": 1,
    "category": "candidate",
    "ticker": "IVBXF"
   },
   {
    "sponsor": "Hansoh BioMedical R&D Company",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Novadip Biosciences",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Privo Technologies",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "National Cancer Institute (NCI)",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "UnitedHealthcare",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Gynecologic Oncology Group",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "The Third Affiliated Hospital of Southern Medical University",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Cytopeutics Sdn. Bhd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "National University of Malaysia",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "TVAX Biomedical",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Mabscale, LLC",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Wuxi Cellular Biopharmaceutical Group Ltd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Breathe Biologics, Inc.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Karyopharm Therapeutics Inc",
    "n": 1,
    "category": "candidate",
    "ticker": "KPTI"
   },
   {
    "sponsor": "Harrow Inc",
    "n": 1,
    "category": "candidate",
    "ticker": "HROW"
   },
   {
    "sponsor": "Cook MyoSite",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Shanghai Vitalgen BioPharma Co., Ltd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Boehringer Ingelheim",
    "n": 1,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "CSPC Megalith Biopharmaceutical Co.,Ltd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Adverum Biotechnologies, Inc.",
    "n": 1,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Jiangsu Topcel-KH Pharmaceutical Co., Ltd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Cartesian Therapeutics",
    "n": 1,
    "category": "watchlist",
    "ticker": ""
   },
   {
    "sponsor": "Beijing Konruns Pharmaceutical Co., Ltd.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Xynomic Pharmaceuticals, Inc.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "GeneCradle Inc",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "BeOne Medicines",
    "n": 1,
    "category": "candidate",
    "ticker": "ONC"
   },
   {
    "sponsor": "West China Hospital",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Gilead Sciences",
    "n": 1,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "iVascular S.L.U.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Takeda Development Center Americas, Inc.",
    "n": 1,
    "category": "major",
    "ticker": ""
   },
   {
    "sponsor": "Biotheus Inc.",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Ocugen",
    "n": 1,
    "category": "candidate",
    "ticker": "OCGN"
   },
   {
    "sponsor": "Acerta Pharma BV",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   },
   {
    "sponsor": "Grace Science, LLC",
    "n": 1,
    "category": "unmapped",
    "ticker": ""
   }
  ],
  "n_trials": 116
 },
 "enrichment": {
  "ADVM": {
   "has_options": false,
   "n_exp": 0,
   "furthest": "",
   "leaps": false,
   "checked_ts": 1787170978.4550867,
   "checked": "2026-08-19"
  },
  "ALNY": {
   "has_options": true,
   "n_exp": 8,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790933992.8039613,
   "checked": "2026-10-02"
  },
  "ARCT": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-03-19",
   "leaps": false,
   "checked_ts": 1790933997.5002425,
   "checked": "2026-10-02"
  },
  "BEAM": {
   "has_options": true,
   "n_exp": 6,
   "furthest": "2028-01-21",
   "leaps": true,
   "checked_ts": 1790934000.7844028,
   "checked": "2026-10-02"
  },
  "BNTX": {
   "has_options": true,
   "n_exp": 11,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934007.3194442,
   "checked": "2026-10-02"
  },
  "CRBU": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-04-16",
   "leaps": false,
   "checked_ts": 1790934011.9143076,
   "checked": "2026-10-02"
  },
  "CRSP": {
   "has_options": true,
   "n_exp": 12,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934020.0037577,
   "checked": "2026-10-02"
  },
  "EDIT": {
   "has_options": true,
   "n_exp": 6,
   "furthest": "2028-01-21",
   "leaps": true,
   "checked_ts": 1790934026.3334088,
   "checked": "2026-10-02"
  },
  "EXAS": {
   "has_options": false,
   "n_exp": 0,
   "furthest": "",
   "leaps": false,
   "checked_ts": 1787170985.4904659,
   "checked": "2026-08-19"
  },
  "GH": {
   "has_options": true,
   "n_exp": 10,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934028.4970279,
   "checked": "2026-10-02"
  },
  "ILMN": {
   "has_options": true,
   "n_exp": 7,
   "furthest": "2028-01-21",
   "leaps": true,
   "checked_ts": 1790934034.0289576,
   "checked": "2026-10-02"
  },
  "IONS": {
   "has_options": true,
   "n_exp": 8,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934037.1765924,
   "checked": "2026-10-02"
  },
  "IOVA": {
   "has_options": true,
   "n_exp": 13,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934040.4814517,
   "checked": "2026-10-02"
  },
  "LXEO": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-05-21",
   "leaps": false,
   "checked_ts": 1790934044.6327794,
   "checked": "2026-10-02"
  },
  "MRNA": {
   "has_options": true,
   "n_exp": 18,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934054.1077933,
   "checked": "2026-10-02"
  },
  "MYGN": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-05-21",
   "leaps": false,
   "checked_ts": 1790934057.2194664,
   "checked": "2026-10-02"
  },
  "NTLA": {
   "has_options": true,
   "n_exp": 6,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934066.5190916,
   "checked": "2026-10-02"
  },
  "NTRA": {
   "has_options": true,
   "n_exp": 10,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934076.6747704,
   "checked": "2026-10-02"
  },
  "PRME": {
   "has_options": true,
   "n_exp": 6,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934081.3668573,
   "checked": "2026-10-02"
  },
  "QURE": {
   "has_options": true,
   "n_exp": 7,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934084.188153,
   "checked": "2026-10-02"
  },
  "RCKT": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-04-16",
   "leaps": false,
   "checked_ts": 1790934089.5989163,
   "checked": "2026-10-02"
  },
  "RGNX": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-04-16",
   "leaps": false,
   "checked_ts": 1790934092.4302254,
   "checked": "2026-10-02"
  },
  "RNA": {
   "has_options": true,
   "n_exp": 3,
   "furthest": "2028-01-21",
   "leaps": true,
   "checked_ts": 1790934095.478774,
   "checked": "2026-10-02"
  },
  "RNAC": {
   "has_options": true,
   "n_exp": 4,
   "furthest": "2027-05-21",
   "leaps": false,
   "checked_ts": 1790934095.9801853,
   "checked": "2026-10-02"
  },
  "SLDB": {
   "has_options": true,
   "n_exp": 5,
   "furthest": "2027-03-19",
   "leaps": false,
   "checked_ts": 1790934098.1431541,
   "checked": "2026-10-02"
  },
  "SRPT": {
   "has_options": true,
   "n_exp": 16,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934100.5487819,
   "checked": "2026-10-02"
  },
  "STOK": {
   "has_options": true,
   "n_exp": 5,
   "furthest": "2027-12-17",
   "leaps": true,
   "checked_ts": 1790934104.1771882,
   "checked": "2026-10-02"
  },
  "TEM": {
   "has_options": true,
   "n_exp": 19,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934107.0529299,
   "checked": "2026-10-02"
  },
  "TSHA": {
   "has_options": true,
   "n_exp": 5,
   "furthest": "2027-04-16",
   "leaps": false,
   "checked_ts": 1790934109.9358635,
   "checked": "2026-10-02"
  },
  "WGS": {
   "has_options": true,
   "n_exp": 13,
   "furthest": "2029-01-19",
   "leaps": true,
   "checked_ts": 1790934114.2917287,
   "checked": "2026-10-02"
  },
  "WVE": {
   "has_options": true,
   "n_exp": 7,
   "furthest": "2028-01-21",
   "leaps": true,
   "checked_ts": 1790934121.8407214,
   "checked": "2026-10-02"
  }
 },
 "iv_scan": {},
 "md_meta": {
  "credits_remaining": 6485,
  "notes": []
 }
}